

[View this email in your browser](#)

MORE TIME, MORE OPTIONS

CLINICAL TRIALS NEWSLETTER

PRESENTED BY **FIGHTCRC** WITH SUPPORT FROM  **MERCK**

A metastatic colorectal cancer diagnosis comes with a lot of decisions, and the first treatment decision may be the most defining one you make. Before you start, you have more options than you might know. **This month, we're focused on what it means to navigate first-line treatment in metastatic CRC: what the term actually means, why timing matters, and what's available right now for patients ready to explore every possibility.**

We want to hear from you!

What do you want to see in our Clinical Trials Newsletter?

LET US KNOW!

FEATURED STORY

First-Line Treatment in Metastatic CRC — Why the Conversation Starts Now

When colorectal cancer is metastatic, the first treatment decision carries significant weight. "First-line treatment" refers to the very first course of therapy you receive after a metastatic CRC diagnosis. It sounds straightforward, but the decision is shaped by

your tumor's biology, your overall health, your goals, and increasingly, by what is being studied in clinical trials right now.

Some clinical trial options are only available before treatment begins. Once therapy starts, that window can close quickly.

Comprehensive biomarker testing, including RAS, BRAF V600E, MSI/dMMR, and HER2, plays a critical role in determining both standard treatment options and clinical trial eligibility. Asking about trials early is one of the most informed steps a patient can take.

Fight CRC is committed to helping patients and care partners understand what first-line treatment means, what questions to ask before starting, and what options may be available at this important stage of care.

To learn more: [Register for our August 27 webinar: Clinical Trials and First-Line Metastatic CRC.](#)

CLINICAL TRIALS & FIRST-LINE METASTATIC CRC

WHAT PATIENTS SHOULD KNOW BEFORE STARTING TREATMENT



Christopher Lieu, M.D.
Professor of Medicine in the Division of Medical
Oncology & Associate Director for Clinical Research
University of Colorado



Bill Thach
Stage IV Rectal Cancer Patient
Research Advocate
Fight CRC



ONLINE WEBINAR

AUGUST 27 | 5-6PM ET

Join Fight CRC for a free webinar for patients, survivors, and care partners. Dr. Christopher Lieu (University of Colorado School of Medicine) and [Fight CRC](#)

[Research Advocate](#) Bill Thach will walk through first-line treatment decisions, how clinical trials fit into care planning, and what to ask your care team before starting treatment.

Supported by Pfizer. Content developed independently by Fight CRC.

JOIN US ON AUGUST 27

[Listen to the audio version of this newsletter!](#)

CLINICAL TRIAL ROUNDUP

Open Trials for Every Stage

This month's roundup features clinical trials for patients with metastatic colorectal cancer across a range of biomarker profiles and treatment stages. Whether you're considering your first treatment or planning what comes next, these are conversations worth having with your care team before treatment decisions are made.

EXPLORE THE AUGUST CLINICAL TRIALS BLOG

Disclaimer: Inclusion in this list does not imply endorsement or a guaranteed benefit. Always consult your healthcare provider to determine whether a clinical trial is appropriate for you.

SPOTLIGHT

Symbiotic-GI-03 – A novel bispecific antibody for Metastatic Colorectal Cancer

Pfizer's Symbiotic-GI-03 clinical trial is evaluating a study medicine called PF-08634404 in adults with metastatic (stage IV) colorectal cancer who have not received anticancer treatment for metastatic disease and do not have BRAF V600E mutations or MSI-H/dMMR tumors.

The study medicine is an investigational bispecific antibody designed to target both PD-1 and VEGF at the same time. Researchers are exploring whether targeting PD-1

(an immune checkpoint) and VEGF (a protein that supports tumor blood vessel growth) at the same time may help the immune system find and attack the cancer cells while also slowing down tumor growth.

Ask your doctor whether your tumor has been tested for key biomarkers, including RAS, BRAF V600E, and MSI/dMMR, and whether a first-line clinical trials such as Symbiotic-GI-03 may be an option for you.

LEARN MORE ABOUT THE SYMBIOTIC-GI-03 CLINICAL TRIAL

BEHIND THE RESEARCH

Every month, this newsletter's clinical trial recommendations are reviewed by Fight CRC's [Medical Advisory Board \(MAB\)](#), a group of leading oncologists, gastroenterologists, geneticists, and researchers who volunteer their expertise to keep our patient education grounded in the best available science.

The MAB works alongside our [Research Advocacy Training and Support \(RATS\)](#) volunteers to bridge clinical science and lived experience. Where advocates bring firsthand perspective on navigating CRC, MAB members bring deep research and clinical expertise. Together they make sure what reaches patients is both accurate and genuinely useful.

MEET THE MEDICAL ADVISORY BOARD

ACTION AND AWARENESS



WE NEED YOUR VOICE!

Join us this August during our [Summer of Action](#) to help grow the [Congressional Colorectal Cancer Caucus](#) and ensure more lawmakers understand the urgent need to prioritize colorectal cancer research, prevention, and patient access.

Whether you have five minutes or an afternoon, there's an opportunity to make your voice heard. [Choose the action](#) that works best for you, and we'll provide everything you need to get started, including talking points, templates, and resources so you can advocate with confidence.

Want to make your voice heard? [Join our next Advocacy Action Hour August 20 \(tomorrow\) at 8:30 p.m. ET](#) and learn how you can help drive change for the colorectal cancer community.

[Prefer Listening? Play the Audio Version](#)



[Take the Quiz!](#)



[Ask Now!](#)



[Search Now!](#)

DONATE TO SUPPORT OUR RESEARCH

Thank you to our sponsors for this month's Clinical Trials:



Johnson & Johnson





© Copyright 2026 Fight Colorectal Cancer
FightCRC.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe](#)